MaxCyte (MXCT)
(Real Time Quote from BATS)
$3.97 USD
-0.13 (-3.17%)
Updated Sep 23, 2024 03:55 PM ET
After-Market: $3.95 -0.02 (-0.50%) 4:10 PM ET
2-Buy of 5 2
F Value F Growth B Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
MXCT 3.97 -0.13(-3.17%)
Will MXCT be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for MXCT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MXCT
MaxCyte, Inc. (MXCT) Reports Q2 Loss, Tops Revenue Estimates
Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Lags Revenue Estimates
MXCT: What are Zacks experts saying now?
Zacks Private Portfolio Services
MaxCyte (MXCT) is on the Move, Here's Why the Trend Could be Sustainable
Does MaxCyte (MXCT) Have the Potential to Rally 85% as Wall Street Analysts Expect?
Recent Price Trend in MaxCyte (MXCT) is Your Friend, Here's Why
Other News for MXCT
MaxCyte (MXCT) Gets a Buy from Craig-Hallum
MaxCyte touts strategic platform license deal with Kamau Therapeutics
MaxCyte, Kamau Therapeutics enter strategic platform license agreement
MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases
MaxCyte Partners with Kamau Therapeutics to Advance Gene Therapies